 |
12 Diseases |  |
0 Trials |
|
0 Trials |  |
6 News |  |
- |||| Selzentry (maraviroc) / ViiV Healthcare, Kaletra + Selzentry ( lopinavir/ritonavir + maraviroc) / Abbott
Off label precription of the existing ones, lopinavir/ritonavir or maraviroc for instance as immunomodulator and in vitro effect vs SARS-COV-2 could kill two birds at the same time. Some LC patients have tried It. More or less 50% who try It have recovered. This is my case (Twitter) - Sep 6, 2022
- Enrollment change, Trial termination, Trial primary completion date: Pilot Assessment of Lopinavir/Ritonavir and Maraviroc (clinicaltrials.gov) - Jun 23, 2015
P4, N=3, Terminated, Sponsor: Rodwick, Barry M., M.D.
N=25 --> 3 | Recruiting --> Terminated | Trial primary completion date: Jul 2011 --> May 2015; unable to enroll expected number of subjects
- Trial primary completion date: Kaletra and Maraviroc in Antiretroviral Therapy (ART)-Naive Patients (KALMAR Study) (clinicaltrials.gov) - Jun 4, 2014
P4, N=1, Terminated, Sponsor: Temple University
N=25 --> 3 | Recruiting --> Terminated | Trial primary completion date: Jul 2011 --> May 2015; unable to enroll expected number of subjects Trial primary completion date: Jul 2011 --> Jun 2014
- Trial termination: Kaletra and Maraviroc in Antiretroviral Therapy (ART)-Naive Patients (KALMAR Study) (clinicaltrials.gov) - Jun 4, 2014
P4, N=1, Terminated, Sponsor: Temple University
Trial primary completion date: Jul 2011 --> Jun 2014 Recruiting --> Terminated; Poor enrollment
- Enrollment change: Kaletra and Maraviroc in Antiretroviral Therapy (ART)-Naive Patients (KALMAR Study) (clinicaltrials.gov) - Jun 4, 2014
P4, N=1, Terminated, Sponsor: Temple University
Recruiting --> Terminated; Poor enrollment N=20 --> 1